⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ACIU News
AC Immune SA
Global Alpha-Emitting Radioligand Therapy Market Size, Share, Trends, and Forecast to 2035 | USD 3.01 Billion Opportunity Driven by Precision Oncology and Isotope Expansion
globenewswire.com
AZN
BMY
LLY
NVS
ACIU
TLX
Parkinson's Disease Market Poised for Expansion During the Forecast Period (2026-2036) Amid JUVMO Approval and Emerging Therapeutic Innovations | DelveInsight
prnewswire.com
ABBV
ANVS
ACIU
BHF
MGNX
NBIX
UCB
AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104
globenewswire.com
ACIU
AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764
globenewswire.com
ACIU
AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)
globenewswire.com
ACIU
AC Immune First Half 2026 Financial and Corporate Update
globenewswire.com
ACIU
Amylin Analogs and Combination Therapies Clinical Trial Landscape Expands as 15+ Leading Companies Accelerate Drug Development | DelveInsight
globenewswire.com
AZN
LLY
NVO
PFE
AMGN
BMY
JNJ
REGN
VKTX
ZETA
CRSP
IONS
AXSM
MRK
GSK
SNY
IMUX
BMEA
ALKS
ALT
AARD
NOV
CARM
CRIS
LPCN
GILD
REG
SPRO
ABSI
ALZN
ANVS
BV
ARCL
ACIU
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026
globenewswire.com
ACIU
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease
globenewswire.com
ACIU
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease
globenewswire.com
ACIU